#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia

John Carroll

Editor & Founder

Back in the mid-80s, David Altshuler worked in Richard Mulligan’s famous Harvard lab, focused on hemoglobinopathies and the glimmering promise of a gene therapy for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

#ASH20: David Alt­shuler and the Ver­tex/CRISPR team hit a his­toric mile­stone in the hunt for a cu­ra­tive gene edit­ing ap­proach to sick­le cell dis­ease, be­ta tha­lassemia

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

#ASH20: David Altshuler and the Vertex/CRISPR team hit a historic milestone in the hunt for a curative gene editing approach to sickle cell disease, beta thalassemia